Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
04/10/2021
Initial Lawsuit
04/10/2021
Lawsuit Progression
06/29/2021
Settlement
04/07/2022
Investigation regarding Champignon’s internal controls over financial reporting, previous acquisitions and acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.
02/17/2021
Champignon Brands announces a restatement of its condensed interim consolidated financial statements and management’s discussion & analysis for the three and six month periods ended March 31, 2020:
“. . . the Company previously recognized intangible assets in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. that aggregated approximately $12 million. Subsequent to the issuance of the Original Financial Statements and MD&A, management determined that the financial statements needed to be restated to correct the accounting for the Acquisitions as the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as result will be recorded as transaction costs in the Company’s statement of loss and comprehensive loss. The restated condensed interim consolidated financial statements and MD&A will reflect this change in the accounting treatment of the assets acquired in these acquisitions. The effect of the restatements does not impact the Company’s cash position.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$0.69 | $0.77 | $-0.08 | -10.78% |
This is a class action on behalf of persons or entities who purchased or otherwise acquired publicly traded Champignon securities between March 27, 2020 and February 17, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(1) Champignon had undisclosed material weaknesses and insufficient financial controls;
(2) Champignon’s previously issued financial statements were false and unreliable;
(3) Champignon’s earlier reported financial statements would need to be restated;
(4) Champignon’s acquisitions involved an undisclosed related party;
(5) as a result of the foregoing and subsequent reporting delays and issues, the British Columbia Securities Commission would suspend Champignon’s from trading;
(6) as a result, Defendants’ statements about Champignon’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
06/29/2021
The court issued an order appointing the lead plaintiff and lead counsel.
11/03/2021
This is a federal securities class action on behalf of persons or entities that purchased or acquired Champignon securities between March 27, 2020 and February 17, 2021, inclusive.
Operative complaint
12/20/2021
A motion to dismiss was filed with the court.
On 04/07/2022, lead counsel Glancy Prongay & Murray LLP announced a proposed class action settlement.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.